Product Development - The company is developing IKT-001, a prodrug of imatinib mesylate, for the treatment of Pulmonary Arterial Hypertension (PAH), with a Phase 2b study expected to start in the second half of 2025[114]. - A bioequivalence study established that a 300 mg dose of IKT-001 is equivalent to 230 mg of imatinib mesylate, and a 500 mg dose is equivalent to 383 mg of imatinib mesylate[116]. - The company has commercialization rights to IKT-001 with patent protection in the U.S. until 2033, with potential extensions until 2045[124]. - The FDA has indicated that the 505(b)(2) pathway is appropriate for the approval of IKT-001, which may grant New Molecular Entity status and market exclusivity[122]. - A recent study confirmed that imatinib was well tolerated in PAH patients, supporting the efficacy of IKT-001[123]. - The company plans to apply for Orphan Drug Designation for IKT-001 once pre-clinical studies are complete[122]. Financial Performance - Research and development expenses for the first quarter of 2025 totaled $10.51 million, a significant increase from $2.75 million in the same period of 2024[131]. - Research and development expenses increased by $7,762,300 or 282.1% to $10,513,579 from $2,751,279 in the prior comparable period[135]. - Selling, general and administrative expenses rose by $3,218,210 or 158.4% to $5,249,291 from $2,031,081 in the prior comparable period[136]. - Net loss for the three months ended March 31, 2025, was $13,678,735, compared to a net loss of $4,649,635 in the prior comparable period, representing an increase of 194.2%[134]. - Interest income surged by $786,546 or 592.6% to $919,271 from $132,725 in the prior comparable period[138]. - As of March 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $93,180,291[140]. - The company incurred net cash used in operating activities of $4,103,530 for the three months ended March 31, 2025, compared to $3,867,018 for the same period in 2024[148]. - Net cash provided by investing activities for the three months ended March 31, 2025, was $21,054,342, significantly higher than $3,311,814 in the prior comparable period[152]. - The company has an accumulated deficit of $108,099,346 as of March 31, 2025[141]. Funding and Future Outlook - The company raised approximately $110 million in a private placement to support the Phase 2b trial for IKT-001, with potential total gross proceeds of up to $275 million if warrants are exercised[122]. - Future funding requirements are anticipated to be substantial as the company continues to develop and seek regulatory approvals for its product candidates[142]. - The company expects to finance its cash needs through a combination of equity offerings, debt financings, and potential collaboration agreements[143]. Corporate Actions - The company has discontinued the development of risvodetinib for Parkinson's disease and has outlicensed the program[115]. - The company agreed to issue 4,979,101 shares of common stock to CorHepta shareholders, with 829,849 shares fully vested at acquisition, 2,489,030 shares as contingent consideration, and 1,660,222 shares for post-merger compensation[163]. - A change in fair value of contingent consideration of $1,164,864 was recorded for the period ended March 31, 2025, included within operating expenses[164]. - The acquired IPR&D asset of $7,357,294 was written off as research and development expense immediately following the acquisition[165].

Exhibit 99.1 Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity —Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension — May 14, 2025 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension ("PAH"), today reported financial results for the quarter ended March 31, 2 ...

Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial HypertensionBOSTON and ATLANTA, May 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension (“PAH”), today reported financial results for the quarter ended March 31, 2025 and highlighted recent developments. “During our first quarter of 2025, we co ...

NEW YORK, May 5, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Inhibikase Therapeutics, Inc. (NASDAQ: IKT) on behalf of the company's shareholders. The investigation seeks to determine whether Inhibikase Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.If you are a shareholder of Inhibikase Therapeutics, Inc. and are interested in obtaining additional information about your rights and options, please visit us at: https://p ...

BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension ("PAH"), today announced the appointment of David McIntyre as Chief Financial Officer, effective April 14, 2025. "David has extensive experience in financial strategy and corporate governance, as well as an established reputation within the life s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 26-3407249 (State or other jurisdiction of ...

Exhibit 99.1 Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity — New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension — March 27, 2025 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension ("PAH"), today reported financial results for the yea ...

Core Viewpoint - Inhibikase Therapeutics, Inc. is advancing its clinical development of IkT-001 for pulmonary arterial hypertension (PAH) and has reported a net loss for 2024 while enhancing its management team to support growth [2][4][7]. Financial Results - The net loss for the year ended December 31, 2024, was $27.5 million, or $1.16 per share, compared to a net loss of $19.1 million, or $3.16 per share in 2023 [4][15]. - Research and development expenses increased to $17.2 million in 2024 from $13.6 million in 2023 [4][14]. - Selling, general and administrative expenses rose to $11.4 million in 2024 from $6.7 million in 2023 [5][14]. - As of December 31, 2024, the company had cash, cash equivalents, and marketable securities totaling $97.5 million [5]. Recent Developments - The company closed a private placement in October 2024, raising approximately $110 million to support the late-stage clinical trial of IkT-001, with potential total gross proceeds of up to $275 million if warrants are exercised [7]. - The company received a "Study May Proceed" letter for the Phase 2b trial of IkT-001 in September 2024, indicating progress in its clinical development [7]. - The management team was strengthened with the appointments of Chris Cabell and John Adams, who are expected to accelerate the development of IkT-001 [2][7].

Core Viewpoint - Inhibikase Therapeutics, Inc. (IKT) has experienced a downtrend, losing 15.4% over the past two weeks, but a hammer chart pattern suggests a potential trend reversal due to increased buying interest [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottom in the stock price, suggesting that selling pressure may be exhausting and that bulls are gaining control [2][4]. - A hammer pattern forms when there is a small candle body with a long lower wick, indicating that the stock opened lower, made a new low, but closed near its opening price, reflecting buying interest [3][4]. Fundamental Analysis - There has been a positive trend in earnings estimate revisions for IKT, with a 4% increase in the consensus EPS estimate over the last 30 days, indicating that analysts expect better earnings than previously predicted [6][7]. - IKT holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [8].

Core Insights - Inhibikase Therapeutics has appointed Chris Cabell, M.D. as President and Head of Research & Development, and John Adams, Ph.D. as Chief Scientific Officer, both with extensive experience in pulmonary arterial hypertension (PAH) [1][2] - The company aims to accelerate the development of IkT-001, an oral prodrug of imatinib mesylate, for the treatment of PAH, with plans to execute a Phase 2 clinical trial [2][6] - Vince Aurentz has joined the Board of Directors, bringing significant experience in corporate strategy and business development from his previous roles in the biopharmaceutical sector [2][5] Leadership Appointments - Chris Cabell, M.D. has a background as Chief Medical Officer at Arena Pharmaceuticals and Chief Executive Officer at CorHepta Pharmaceuticals, with a focus on cardiology and PAH [3] - John Adams, Ph.D. co-founded CorHepta and previously held senior positions at Iambic Therapeutics and Reneo Pharmaceuticals, specializing in research and translational science [4] - Vince Aurentz has held key leadership roles, including Executive Vice President at Arena Pharmaceuticals, contributing to corporate strategy and business development [5] Company Overview - Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary diseases [6] - The company's lead product, IkT-001, targets PAH and is positioned as a potential innovative therapeutic option for patients suffering from this condition [6]